Valion Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Valion Bio, Inc. on August 27, 2026, covering events occurring on August 27, 2026, and August 31, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in San Antonio, Texas. The filing primarily addresses a material definitive agreement regarding a securities purchase and the appointment of two new directors.
Key Financial Metrics and Transaction Details
The filing details a specific securities transaction rather than providing standard periodic financial statements (revenue, profit, or cash flow). Key financial data points from the transaction include:
- Total Aggregate Purchase Price: $7,737,000 paid by investor 3i, LP.
- Cash Proceeds to Company: $1,500,000 in immediately available funds.
- Retained by Investor: $6,137,000 retained by 3i to satisfy overdue cash true-up payments and $100,000 for legal fees.
- Securities Issued:
- 100 Series B Non-Voting Convertible Preferred Shares.
- 7,637 Series C Non-Voting Convertible Preferred Shares.
- Warrants to purchase 3,077 shares of Common Stock (Series B) and 1,053,969 shares of Common Stock (Series C).
- Exercise Price: $3.62 per share for all warrants issued in this closing.
- Stock Split: The warrant share counts reflect a 1-for-25 reverse stock split effective August 31, 2026.
The filing does not provide clear values for the Company's total revenue, net profit, operating cash flow, gross margins, total debt, or overall liquidity position outside of this specific transaction.
Material Changes and Corporate Actions
Significant changes reported in this filing include:
- Capital Structure Adjustment: Execution of a closing under prior Series B and Series C Preferred Purchase Agreements, resulting in the issuance of preferred stock and warrants to 3i, LP.
- Board Composition: Appointment of two new directors effective August 27, 2026:
- Jared Malbin: Former COO of Lucid Capital Markets with over 25 years of experience in financial services, compliance, and capital markets.
- Thomas Jensen: CEO of Allarity Therapeutics, Inc., with over 20 years of experience in biotechnology and oncology.
- Registration Obligation: The Company agreed to file a registration statement within 30 days of the closing to permit the resale of the issued securities by 3i.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements regarding the Company's future performance, noting that actual results may differ materially due to risks and uncertainties. Specific contingencies and commitments include:
- Resale Registration: The Company must have the registration statement declared effective by the SEC no later than 60 days from the closing date (approximately October 31, 2026) and keep it effective until 3i sells all covered securities.
- True-Up Payments: A significant portion of the transaction value ($6.137 million) was applied to satisfy overdue cash true-up payments, indicating prior financial obligations under the Series C Certificate of Designation.
- Regulatory Risks: As an emerging growth company, the Company faces standard risks associated with clinical-stage biotechnology operations and capital market dependencies.
Investor Verification Checklist
- Verify the status of the "overdue cash true-up payments" referenced in the transaction to understand the Company's prior liquidity constraints.
- Confirm the filing and effectiveness date of the registration statement required for the resale of the 1,057,046 shares of Common Stock underlying the new warrants.
- Review the full text of the Series B and Series C Preferred Purchase Agreements to understand the conversion mechanics and voting rights (or lack thereof) of the new preferred shares.
- Monitor the impact of the 1-for-25 reverse stock split on the Company's market capitalization and share liquidity.
- Assess the strategic value of the new board appointments, specifically their experience in capital markets and oncology, relative to the Company's current development pipeline.